DexCom, Inc. (DXCM)
Company Info
Highlights
$33.52B
$1.33
64.27
1.32
$4.15B
$2.46B
$889.80M
$57.52 - $132.09
$97.68
3.73%
2.47
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
DexCom, Inc. (DXCM) returned 9.91% year-to-date (YTD) and -34.93% over the past 12 months. Over the past 10 years, DXCM delivered an annualized return of 17.38%, outperforming the S&P 500 benchmark at 10.89%.
DXCM
9.91%
24.66%
12.65%
-34.93%
-3.79%
17.38%
^GSPC (Benchmark)
1.30%
12.79%
1.49%
12.35%
15.12%
10.89%
Monthly Returns
The table below presents the monthly returns of DXCM, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 11.65% | 1.77% | -22.72% | 4.52% | 19.75% | 9.91% | |||||||
| 2024 | -2.21% | -5.18% | 20.54% | -8.15% | -6.77% | -4.54% | -40.18% | 2.24% | -3.32% | 5.13% | 10.66% | -0.28% | -37.33% |
| 2023 | -5.43% | 3.66% | 4.66% | 4.44% | -3.36% | 9.59% | -3.07% | -18.93% | -7.61% | -4.79% | 30.05% | 7.42% | 9.58% |
| 2022 | -19.83% | -3.85% | 23.60% | -20.14% | -27.08% | 0.06% | 10.13% | 0.16% | -2.03% | 49.96% | -3.73% | -2.61% | -15.64% |
| 2021 | 1.39% | 6.12% | -9.65% | 7.43% | -4.33% | 15.60% | 20.73% | 2.70% | 3.29% | 13.96% | -9.73% | -4.56% | 45.23% |
| 2020 | 10.06% | 14.64% | -2.44% | 24.48% | 12.86% | 7.16% | 7.43% | -2.33% | -3.10% | -22.48% | 0.03% | 15.65% | 69.02% |
| 2019 | 17.72% | -1.21% | -14.52% | 1.65% | 0.19% | 23.53% | 4.69% | 9.40% | -13.04% | 3.35% | 47.37% | -3.77% | 82.59% |
| 2018 | 1.41% | -3.54% | 32.10% | -1.32% | 20.24% | 7.94% | 0.16% | 51.77% | -0.93% | -7.18% | -2.40% | -7.55% | 108.75% |
| 2017 | 32.58% | -1.25% | 8.41% | -7.99% | -14.26% | 9.44% | -8.94% | 12.01% | -34.42% | -8.09% | 29.93% | -1.78% | -3.87% |
| 2016 | -12.97% | -8.73% | 4.38% | -5.20% | 0.17% | 23.01% | 16.26% | -1.24% | -3.77% | -10.75% | -16.55% | -8.56% | -27.11% |
| 2015 | 8.59% | 1.61% | 2.63% | 8.39% | 6.14% | 11.52% | 5.84% | 11.21% | -8.80% | -2.96% | 2.04% | -3.67% | 48.77% |
| 2014 | 14.26% | 11.47% | -8.29% | -21.57% | 4.07% | 17.48% | -4.99% | 17.30% | -9.52% | 12.40% | 14.48% | 6.98% | 55.46% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of DXCM is 23, meaning it’s performing worse than 77% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for DexCom, Inc. (DXCM) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the DexCom, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the DexCom, Inc. was 94.61%, occurring on Nov 20, 2008. Recovery took 1185 trading sessions.
The current DexCom, Inc. drawdown is 47.50%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -94.61% | May 5, 2006 | 643 | Nov 20, 2008 | 1185 | Aug 8, 2013 | 1828 |
| -63.25% | Nov 18, 2021 | 847 | Apr 4, 2025 | — | — | — |
| -56.37% | Sep 18, 2015 | 532 | Oct 26, 2017 | 176 | Jul 11, 2018 | 708 |
| -39.59% | Mar 6, 2014 | 44 | May 7, 2014 | 129 | Nov 7, 2014 | 173 |
| -36.81% | Feb 21, 2020 | 19 | Mar 18, 2020 | 20 | Apr 16, 2020 | 39 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of DexCom, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of DexCom, Inc., comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -2.6%.
Valuation
The Valuation section provides an overview of how DexCom, Inc. is priced in the market compared to other companies in the Diagnostics & Research industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for DXCM, comparing it with other companies in the Diagnostics & Research industry. Currently, DXCM has a P/E ratio of 64.3. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for DXCM compared to other companies in the Diagnostics & Research industry. DXCM currently has a PEG ratio of 1.3. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for DXCM relative to other companies in the Diagnostics & Research industry. Currently, DXCM has a P/S ratio of 8.1. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for DXCM in comparison with other companies in the Diagnostics & Research industry. Currently, DXCM has a P/B value of 14.8. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |